Compare Charles River Laboratories Intl. Inc (CRL) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $286.67 (market cap $13.46B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.61. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRL | EMLC | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Fixed Income |
52-Week High | $282.00 | $26.59 |
52-Week Low | $145.57 | $24.83 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
EMLC trades at $25.615, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.13-$0.14 per share. Emerging market debt exposure provides yield advantages over developed markets, though volatility remains a consideration.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market yield premiums. Key opportunities include attractive fixed income returns compared to Treasury bonds, while risks center on emerging market volatility and inflation concerns. The technical bullish signal supports near-term price stability with potential for gradual appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
